Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBIT Margin (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed EBIT Margin for 16 consecutive years, with 83.06% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin rose 1558.0% year-over-year to 83.06%, compared with a TTM value of 79.83% through Sep 2025, down 3302.0%, and an annual FY2024 reading of 101.32%, down 9035.0% over the prior year.
  • EBIT Margin was 83.06% for Q3 2025 at China Pharma Holdings, down from 63.57% in the prior quarter.
  • Across five years, EBIT Margin topped out at 48.14% in Q4 2022 and bottomed at 150.44% in Q2 2024.
  • Average EBIT Margin over 5 years is 44.38%, with a median of 41.56% recorded in 2023.
  • The sharpest move saw EBIT Margin crashed -14258bps in 2024, then surged 8687bps in 2025.
  • Year by year, EBIT Margin stood at 47.14% in 2021, then rose by 2bps to 48.14% in 2022, then decreased by -23bps to 37.1% in 2023, then crashed by -384bps to 105.47% in 2024, then increased by 21bps to 83.06% in 2025.
  • Business Quant data shows EBIT Margin for CPHI at 83.06% in Q3 2025, 63.57% in Q2 2025, and 66.76% in Q1 2025.